Ser216
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser216  -  CDC25C (human)

Site Information
sGLyRsPsMPENLNR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448418
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 116 ) , [32P] ATP in vitro ( 104 ) , [32P] bio-synthetic labeling ( 104 , 113 , 117 ) , electrophoretic mobility shift ( 101 , 110 , 112 ) , flow cytometry ( 106 ) , immunoprecipitation ( 2 , 9 , 14 ) , mass spectrometry ( 1 , 4 , 8 , 13 , 15 , 17 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 34 , 35 , 37 , 39 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 79 , 81 , 82 , 90 , 94 ) , mutation of modification site ( 38 , 104 , 105 , 109 , 112 , 113 ) , peptide sequencing ( 117 ) , phospho-antibody ( 2 , 3 , 6 , 7 , 9 , 11 , 12 , 14 , 33 , 36 , 42 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 80 , 83 , 84 , 85 , 87 , 89 , 91 , 92 , 93 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 111 , 118 ) , phosphoamino acid analysis ( 117 ) , phosphopeptide mapping ( 116 , 117 ) , western blotting ( 2 , 3 , 6 , 7 , 9 , 11 , 12 , 14 , 33 , 36 , 38 , 42 , 72 , 73 , 74 , 76 , 77 , 78 , 80 , 83 , 84 , 85 , 87 , 89 , 97 , 99 , 102 , 103 , 106 , 111 , 116 , 118 )
Disease tissue studied:
ataxia-telangiectasia ( 111 ) , bladder cancer ( 3 , 11 ) , breast cancer ( 13 , 20 , 33 , 70 , 71 , 75 , 77 ) , breast ductal carcinoma ( 13 , 70 , 71 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, surrounding tissue ( 4 ) , breast cancer, triple negative ( 4 , 13 ) , colorectal cancer ( 80 , 99 , 118 ) , colorectal carcinoma ( 80 , 99 , 118 ) , gastric cancer ( 31 , 39 , 40 ) , gastric carcinoma ( 31 , 39 , 40 ) , leukemia ( 43 , 45 , 73 , 79 , 94 , 106 , 110 ) , acute myelogenous leukemia ( 73 , 106 ) , chronic myelogenous leukemia ( 43 , 45 , 79 , 94 , 110 ) , lung cancer ( 15 , 20 , 41 , 74 , 85 , 87 , 99 ) , non-small cell lung cancer ( 20 , 41 , 74 , 87 , 99 ) , non-small cell lung adenocarcinoma ( 15 , 41 , 74 ) , non-small cell squamous cell lung carcinoma ( 41 ) , lymphoma ( 73 ) , neuroblastoma ( 109 ) , prostate cancer ( 7 , 84 , 89 ) , fibrosarcoma of soft tissue ( 6 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 37 ) , 293 (epithelial) ( 25 , 26 , 27 , 28 , 29 , 30 , 80 , 101 ) , 786-O (renal) [VHL (human), transfection] ( 8 ) , 786-O (renal) ( 8 ) , A549 (pulmonary) ( 85 ) , AG04405 (fibroblast) ( 111 ) , agranulocyte-blood ( 103 ) , BJAB (B lymphocyte) ( 78 ) , breast ( 4 , 13 ) , BT-20 (breast cell) ( 20 ) , BT-549 (breast cell) ( 20 ) , C3ABR (lymphoblastoid) ( 111 ) , COS (fibroblast) ( 104 ) , DF1 (fibroblast) ( 2 , 108 ) , DU 145 (prostate cell) ( 7 , 84 , 92 ) , embryo ( 72 , 98 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 21 ) , Flp-In T-Rex-293 (epithelial) ( 21 ) , H2077 (pulmonary) ( 20 ) , H322M (pulmonary) ( 20 ) , HCC2279 (pulmonary) ( 74 ) , HCT116 (intestinal) ( 80 , 99 , 101 , 118 ) , HEK293T (epithelial) ( 113 ) , HeLa (cervical) ( 1 , 12 , 19 , 36 , 38 , 49 , 50 , 51 , 52 , 53 , 54 , 66 , 67 , 68 , 72 , 97 , 102 , 105 , 108 , 112 , 116 , 117 ) , HepG2 (hepatic) ( 57 ) , HOP62 (pulmonary) ( 20 ) , HSC536 (lymphoblast) ( 42 ) , HT1080 (fibroblast) ( 6 ) , J82 (bladder cell) ( 11 ) , Jurkat (T lymphocyte) ( 17 , 23 , 24 , 32 , 34 , 35 , 44 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 69 , 81 , 83 , 90 , 116 ) , K562 (erythroid) ( 19 , 43 , 45 , 79 , 82 , 94 , 110 ) , L3 (lymphoblastoid) ( 111 ) , lung ( 15 ) , MCF-7 (breast cell) ( 33 , 70 , 71 , 76 , 77 ) , MDA-MB-231 (breast cell) ( 20 , 76 ) , MDA-MB-435 (breast cell) ( 107 ) , MDA-MB-468 (breast cell) ( 20 ) , MKN-45 (gastric) ( 31 , 39 , 40 ) , mononuclear ( 73 ) , MRC5 (fibroblast) ( 87 , 111 ) , MV4-11 (macrophage) ( 73 ) , NCI-H1299 (pulmonary) ( 99 ) , NCI-H1395 (pulmonary) ( 20 ) , NCI-H1568 (pulmonary) ( 20 ) , NCI-H1650 (pulmonary) ( 46 , 47 , 48 ) , NCI-H1703 (squamous) ( 41 ) , NCI-H2030 (pulmonary) ( 20 ) , NCI-H2228 (pulmonary) ( 56 ) , NCI-H322 (pulmonary) ( 20 ) , NCI-H3255 (pulmonary) ( 55 ) , NCI-H358 (pulmonary) ( 87 ) , NCI-H647 (pulmonary) ( 20 ) , NHBE (epithelial) ( 87 ) , OCI/AML2 (myeloid) ( 106 ) , OVCAR3 (ovarian) ( 91 ) , PC3 (prostate cell) ( 89 , 92 , 101 ) , RT4 (bladder cell) ( 11 ) , SK-N-MC (neural crest) ( 109 ) , SU-DHL-4 (B lymphocyte) ( 95 ) , T47D (breast cell) ( 75 ) , THP1 (myeloid) ( 73 ) , U-937 (myeloid) ( 73 ) , U2OS (bone cell) [GR (human)] ( 93 , 96 ) , UMUC3 (bladder cell) ( 3 ) , UMUC3R (bladder cell) ( 3 ) , Vero (epithelial) ( 2 )

Upstream Regulation
Regulatory protein:
ATM (human) ( 111 ) , CDC6 (human) ( 3 ) , EMP2 (human) ( 11 ) , ERK1 (human) ( 33 ) , ERK2 (human) ( 33 ) , FLT3 (human) ( 73 ) , Geminin (human) ( 99 ) , HMGA2 (human) ( 6 ) , NPM1 (human) ( 42 ) , p16-INK4A iso5 (human) ( 87 ) , P38A (human) ( 106 )
Putative in vivo kinases:
BRSK1 iso2 (human) ( 100 ) , TAK1 (human) ( 104 )
Kinases, in vitro:
BRSK1 iso2 (human) ( 100 ) , Chk1 (human) ( 10 , 102 , 104 , 105 , 110 , 112 , 113 , 115 , 116 ) , Chk2 (human) ( 86 , 88 , 110 , 111 , 113 ) , MAPKAPK2 (human) ( 96 ) , MARK3 (human) ( 110 , 114 ) , TAK1 (human) ( 104 )
Treatments:
arsenite ( 97 ) , bleomycin ( 12 ) , caffeine ( 75 , 77 , 87 , 99 , 111 ) , cisplatin ( 3 ) , CT-32615 ( 95 ) , DATS ( 92 ) , dolastatin_10 ( 9 ) , etoposide ( 33 ) , galiellalactone ( 7 ) , grape_seed_extract ( 84 ) , HHV-6A ( 103 ) , hydroxyurea ( 78 , 110 ) , IOA ( 76 ) , ionizing_radiation ( 72 , 74 , 77 , 97 , 105 , 110 , 111 , 112 , 113 , 118 ) , MG132 ( 2 , 12 , 36 ) , monastrol ( 9 ) , NAC ( 92 ) , nocodazole ( 9 , 42 , 78 , 116 ) , peptide inhibitor ( 83 ) , PKC412 ( 73 ) , plumbagin ( 85 ) , silibinin ( 89 ) , silymarin ( 89 ) , siRNA ( 99 ) , taxol ( 9 ) , THIF ( 75 ) , U0126 ( 77 ) , UCN-01 ( 110 , 112 , 118 ) , UV ( 36 , 93 , 96 )

Downstream Regulation
Effects of modification on CDC25C:
enzymatic activity, inhibited ( 116 ) , intracellular localization ( 78 , 112 , 114 ) , molecular association, regulation ( 78 , 96 , 105 , 108 , 114 , 116 , 117 )
Effects of modification on biological processes:
cell cycle regulation ( 10 , 33 , 78 , 91 , 95 , 96 , 105 , 116 )
Induce interaction with:
14-3-3 beta (human) ( 78 , 96 , 105 , 108 , 114 , 116 ) , 14-3-3 epsilon (human) ( 96 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Chiu HC, et al. (2016) Suppression of Vimentin Phosphorylation by the Avian Reovirus p17 through Inhibition of CDK1 and Plk1 Impacting the G2/M Phase of the Cell Cycle. PLoS One 11, e0162356
27603133   Curated Info

3

Chen S, et al. (2016) Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. Oncotarget 7, 40362-40376
27246979   Curated Info

4

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

5

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

6

Natarajan S, et al. (2016) High Mobility Group A2 protects cancer cells against telomere dysfunction. Oncotarget 7, 12761-82
26799419   Curated Info

7

García V, et al. (2016) Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. Oncotarget 7, 4490-506
26683224   Curated Info

8

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

9

Cho YC, et al. (2015) Cell cycle-dependent Cdc25C phosphatase determines cell survival by regulating apoptosis signal-regulating kinase 1. Cell Death Differ 22, 1605-17
25633196   Curated Info

10

Han X, et al. (2015) Phosphorylation of Minichromosome Maintenance 3 (MCM3) by Checkpoint Kinase 1 (Chk1) Negatively Regulates DNA Replication and Checkpoint Activation. J Biol Chem 290, 12370-8
25809478   Curated Info

11

Li CF, et al. (2015) The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. Oncotarget 6, 9220-39
25940704   Curated Info

12

Osorio-Zambrano WF, Davey S (2015) Chk1 Activation Protects Rad9A from Degradation as Part of a Positive Feedback Loop during Checkpoint Signalling. PLoS One 10, e0144434
26658951   Curated Info

13

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

14

Chaudhary N, et al. (2014) SMAR1 coordinates HDAC6-induced deacetylation of Ku70 and dictates cell fate upon irradiation. Cell Death Dis 5, e1447
25299772   Curated Info

15

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

16

Lossaint G, et al. (2013) FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling. Mol Cell 51, 678-90
23993743   Curated Info

17

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

18

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

19

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

20

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

21

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

22

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

23

Guo A (2012) CST Curation Set: 13866; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

24

Mulhern D (2012) CST Curation Set: 13759; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

25

Mulhern D (2011) CST Curation Set: 12822; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

26

Mulhern D (2011) CST Curation Set: 12824; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

27

Mulhern D (2011) CST Curation Set: 12825; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

28

Mulhern D (2011) CST Curation Set: 12827; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

29

Mulhern D (2011) CST Curation Set: 12828; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

30

Mulhern D (2011) CST Curation Set: 12829; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

31

Moritz A (2011) CST Curation Set: 11943; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

32

Possemato A (2010) CST Curation Set: 10791; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

33

Wei F, Xie Y, Tao L, Tang D (2010) Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal 22, 1783-9
20637859   Curated Info

34

Possemato A (2010) CST Curation Set: 10778; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

35

Possemato A (2010) CST Curation Set: 10730; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

36

Kasahara K, et al. (2010) 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J 29, 2802-12
20639859   Curated Info

37

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

38

Bagheri-Yarmand R, et al. (2010) Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70, 5085-95
20530684   Curated Info

39

Moritz A (2010) CST Curation Set: 9280; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

40

Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

41

Moritz A (2010) CST Curation Set: 9241; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

42

Du W, Zhou Y, Pike S, Pang Q (2010) NPM phosphorylation stimulates Cdk1, overrides G2/M checkpoint and increases leukemic blasts in mice. Carcinogenesis 31, 302-10
19933706   Curated Info

43

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Moritz A (2010) CST Curation Set: 8865; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

45

Moritz A (2010) CST Curation Set: 8864; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

46

Possemato A (2009) CST Curation Set: 8048; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

47

Possemato A (2009) CST Curation Set: 8049; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

48

Possemato A (2009) CST Curation Set: 8051; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

49

Zhou J (2009) CST Curation Set: 7618; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

50

Zhou J (2009) CST Curation Set: 7617; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

51

Zhou J (2009) CST Curation Set: 7615; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

52

Zhou J (2009) CST Curation Set: 7614; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

53

Zhou J (2009) CST Curation Set: 7616; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

54

Zhou J (2009) CST Curation Set: 7613; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

55

Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

56

Possemato A (2009) CST Curation Set: 7410; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

57

Possemato A (2009) CST Curation Set: 7407; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

58

Possemato A (2009) CST Curation Set: 7130; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

59

Possemato A (2009) CST Curation Set: 7128; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

60

Possemato A (2009) CST Curation Set: 7126; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

61

Possemato A (2009) CST Curation Set: 7124; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

62

Zhou J (2009) CST Curation Set: 6543; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

63

Zhou J (2009) CST Curation Set: 6544; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

64

Zhou J (2009) CST Curation Set: 6541; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

65

Zhou J (2009) CST Curation Set: 6542; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

66

Zhou J (2009) CST Curation Set: 6344; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

67

Zhou J (2009) CST Curation Set: 6345; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

68

Zhou J (2009) CST Curation Set: 6342; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

69

Possemato A (2009) CST Curation Set: 5910; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

70

Possemato A (2008) CST Curation Set: 5240; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

71

Possemato A (2008) CST Curation Set: 5239; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

72

Sidi S, et al. (2008) Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133, 864-77
18510930   Curated Info

73

Odgerel T, et al. (2008) The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Oncogene 27, 3102-10
18071308   Curated Info

74

Kodym E, Kodym R, Choy H, Saha D (2008) Sustained metaphase arrest in response to ionizing radiation in a non-small cell lung cancer cell line. Radiat Res 169, 46-58
18159951   Curated Info

75

Vauzour D, et al. (2007) Inhibition of cellular proliferation by the genistein metabolite 5,7,3',4'-tetrahydroxyisoflavone is mediated by DNA damage and activation of the ATR signalling pathway. Arch Biochem Biophys 468, 159-66
17976513   Curated Info

76

Kuo PL, Chen CY, Hsu YL (2007) Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res 67, 7406-20
17671211   Curated Info

77

Yan Y, Black CP, Cowan KH (2007) Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 26, 4689-98
17297454   Curated Info

78

Choudhuri T, et al. (2007) The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol 81, 6718-30
17409144   Curated Info

79

Possemato A (2007) CST Curation Set: 2723; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

80

Geng L, Zhang X, Zheng S, Legerski RJ (2007) Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B. Mol Cell Biol 27, 2625-35
17242184   Curated Info

81

Possemato A (2007) CST Curation Set: 2647; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

82

Possemato A (2007) CST Curation Set: 2629; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

83

Sha SK, et al. (2007) Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther 6, 147-53
17237275   Curated Info

84

Agarwal C, Tyagi A, Agarwal R (2006) Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther 5, 3294-302
17172433   Curated Info

85

Hsu YL, et al. (2006) Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 318, 484-94
16632641   Curated Info

86

Oliver AW, et al. (2006) Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J 25, 3179-90
16794575   Curated Info

87

Eymin B, et al. (2006) p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 26, 4339-50
16705183   Curated Info

88

Bahassi el M, et al. (2006) Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage. Mutat Res 596, 166-76
16481012   Curated Info

89

Deep G, et al. (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25, 1053-69
16205633   Curated Info

90

Rush J (2005) CST Curation Set: 924; Year: 2005; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

91

Tyagi A, et al. (2005) Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26, 1978-87
15975956   Curated Info

92

Xiao D, et al. (2005) Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. Oncogene 24, 6256-68
15940258   Curated Info

93

Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19, 1162-74
15870257   Curated Info

94

Moritz A (2005) CST Curation Set: 704; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

95

Hideshima T, et al. (2005) Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 24, 3121-9
15735676   Curated Info

96

Manke IA, et al. (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17, 37-48
15629715   Curated Info

97

Yih LH, et al. (2005) Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells. Carcinogenesis 26, 53-63
15471901   Curated Info

98

Conn CW, Lewellyn AL, Maller JL (2004) The DNA damage checkpoint in embryonic cell cycles is dependent on the DNA-to-cytoplasmic ratio. Dev Cell 7, 275-81
15296723   Curated Info

99

Zhu W, Chen Y, Dutta A (2004) Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. Mol Cell Biol 24, 7140-50
15282313   Curated Info

100

Lu R, Niida H, Nakanishi M (2004) Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function. J Biol Chem 279, 31164-70
15150265   Curated Info

101

Singh SV, et al. (2004) Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem 279, 25813-22
15073169   Curated Info

102

Ng CP, et al. (2004) Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem 279, 8808-19
14681223   Curated Info

103

De Bolle L, et al. (2004) Human herpesvirus 6 infection arrests cord blood mononuclear cells in G(2) phase of the cell cycle. FEBS Lett 560, 25-9
14987992   Curated Info

104

Müller J, Ritt DA, Copeland TD, Morrison DK (2003) Functional analysis of C-TAK1 substrate binding and identification of PKP2 as a new C-TAK1 substrate. EMBO J 22, 4431-42
12941695   Curated Info

105

Bulavin DV, et al. (2003) Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 5, 545-51
12766774   Curated Info

106

Tarn C, Zou L, Hullinger RL, Andrisani OM (2002) Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol 76, 9763-72
12208955   Curated Info

107

Tan M, et al. (2002) Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9, 993-1004
12049736   Curated Info

108

Bulavin DV, et al. (2001) Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411, 102-7
11333986   Curated Info

109

Smits VA, et al. (2000) Negative growth regulation of SK-N-MC cells by bFGF defines a growth factor-sensitive point in G2. J Biol Chem 275, 19375-81
10770932   Curated Info

110

Busby EC, et al. (2000) The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60, 2108-12
10786669   Curated Info

111

Zhou BB, et al. (2000) Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 275, 10342-8
10744722   Curated Info

112

Graves PR, et al. (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275, 5600-5
10681541   Curated Info

113

Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-7
9836640   Curated Info

114

Peng CY, et al. (1998) C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ 9, 197-208
9543386   Curated Info

115

Sanchez Y, et al. (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-501
9278511   Curated Info

116

Peng CY, et al. (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277, 1501-5
9278512   Curated Info

117

Ogg S, Gabrielli B, Piwnica-Worms H (1994) Purification of a serine kinase that associates with and phosphorylates human Cdc25C on serine 216. J Biol Chem 269, 30461-9
7982962   Curated Info

118

Tian H, Faje AT, Lee SL, Jorgensen TJ Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia 4, 171-80
11896572   Curated Info